LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 2 of total 2

Search options

  1. Article ; Online: Effectiveness of inhalation technique assessment service for patients with Respimat® inhaler.

    Rossi, Vilma / Salimäki, Johanna / Sandler, Charlotta / Airaksinen, Marja / Kauppi, Paula

    Pulmonary pharmacology & therapeutics

    2021  Volume 71, Page(s) 102077

    Abstract: Objectives: The objective of this study was to examine how Inhalation Technique Assessment Service (ITAS) by community pharmacies affect patients' inhalation techniques when using the Respimat® soft mist inhaler. The inhaler was simultaneously updated ... ...

    Abstract Objectives: The objective of this study was to examine how Inhalation Technique Assessment Service (ITAS) by community pharmacies affect patients' inhalation techniques when using the Respimat® soft mist inhaler. The inhaler was simultaneously updated into a reusable inhaler. The study focused on the Respimat® inhaler because its use is known to be challenging for patients.
    Methods: The study was performed as a pre-post design in 33 community pharmacies (CPs) in Finland. Patients' inhalation technique was assessed before ITAS (baseline) and immediately after ITAS (follow-up 1). Follow-up 2 was performed when the patient came to the pharmacy for a refill (1-3 months after the baseline and the follow-up 1). A Respimat specific twenty item checklist was used to assess inhalation technique. The checklist included 1) preparation steps before the first use of the Respimat® inhaler (8 items) and 2) daily use steps of the Respimat® inhaler (12 items). After ITAS, the patients received a brief questionnaire to assess their asthma/COPD history.
    Results: A total of 228 patients were enrolled at the first visit (mean age 67.8 years, 61.0% female, 85.5% had previous Respimat® use experience) and 42 of them attended the follow-up 2, 1-3 months later (mean age 70.1 years, 69.0% female, 92.9% had previous Respimat® use experience. The median number of the steps performed correctly increased from 17/20 at the baseline to all the 20 steps at the follow-up 1 (p < 0.001). At the baseline, 27.6% of the patients (n = 228) performed all preparation steps correctly, while 87.3% at the follow-up 1 and 71.4% at the follow-up 2. The percentage of the patients with acceptable inhalation technique (all critical daily use steps correct) increased from 69.7% at the baseline to 93.0% at the follow-up 1 (p < 0.001). The corresponding figure at the follow-up 2 was 69.0%. At the baseline, 30.3% of patients had optimal inhalation technique (all daily use steps correct). At the follow-up 1 corresponding figure was 85.1%, and 54.8% at the follow-up 2.
    Conclusions: A pharmacist-led intervention significantly improved asthma and COPD patients' inhalation technique with the Respimat® inhaler. Significant improvements were found in the daily use steps and the preparation steps before the first use.
    MeSH term(s) Administration, Inhalation ; Aged ; Asthma/drug therapy ; Bronchodilator Agents/therapeutic use ; Female ; Humans ; Male ; Nebulizers and Vaporizers ; Pulmonary Disease, Chronic Obstructive/drug therapy
    Chemical Substances Bronchodilator Agents
    Language English
    Publishing date 2021-09-15
    Publishing country England
    Document type Journal Article
    ZDB-ID 1399707-5
    ISSN 1522-9629 ; 1094-5539
    ISSN (online) 1522-9629
    ISSN 1094-5539
    DOI 10.1016/j.pupt.2021.102077
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Prulifloxacin: a new antibacterial fluoroquinolone.

    Prats, Guillem / Rossi, Vilma / Salvatori, Enrica / Mirelis, Beatriz

    Expert review of anti-infective therapy

    2006  Volume 4, Issue 1, Page(s) 27–41

    Abstract: In the last few years, the antimicrobial activity, efficacy and relative safety of fluoroquinolones have made them attractive for the treatment of community-acquired and nosocomial infections. Prulifloxacin is a new fluoroquinolone antibacterial agent ... ...

    Abstract In the last few years, the antimicrobial activity, efficacy and relative safety of fluoroquinolones have made them attractive for the treatment of community-acquired and nosocomial infections. Prulifloxacin is a new fluoroquinolone antibacterial agent with a broad spectrum of activity against Gram-positive and -negative bacteria. Prulifloxacin is available for oral use, and after absorption is metabolized in to the active form, ulifloxacin. It exhibits good penetration in target tissues and a long elimination half-life, allowing once-daily administration. A number of randomized, controlled clinical trials carried out in Europe demonstrated the efficacy of prulifloxacin in the treatment of urinary tract (acute uncomplicated and complicated) and respiratory tract infections (acute exacerbations of chronic bronchitis), in comparison with the most widely used drugs such as ciprofloxacin, co-amoxiclav and pefloxacin. Prulifloxacin was generally well tolerated. The most frequent adverse reactions observed in clinical trials were gastric pain, diarrhea, nausea and skin rash. This review focuses on the characteristics of prulifloxacin, summarizing the relevant preclinical and clinical data.
    MeSH term(s) Anti-Bacterial Agents/adverse effects ; Anti-Bacterial Agents/chemistry ; Anti-Bacterial Agents/pharmacology ; Anti-Bacterial Agents/therapeutic use ; Bacterial Infections/drug therapy ; Bacterial Infections/microbiology ; Clinical Trials as Topic ; Community-Acquired Infections/drug therapy ; Community-Acquired Infections/microbiology ; Cross Infection/drug therapy ; Cross Infection/microbiology ; Dioxolanes/adverse effects ; Dioxolanes/chemistry ; Dioxolanes/pharmacology ; Dioxolanes/therapeutic use ; Drug Resistance, Bacterial ; Fluoroquinolones/adverse effects ; Fluoroquinolones/chemistry ; Fluoroquinolones/pharmacology ; Fluoroquinolones/therapeutic use ; Gram-Negative Bacteria/drug effects ; Gram-Positive Bacteria/drug effects ; Humans ; Microbial Sensitivity Tests ; Piperazines/adverse effects ; Piperazines/chemistry ; Piperazines/pharmacology ; Piperazines/therapeutic use ; Quinolones/adverse effects ; Quinolones/chemistry ; Quinolones/pharmacology ; Quinolones/therapeutic use ; Respiratory Tract Infections/drug therapy ; Respiratory Tract Infections/microbiology ; Treatment Outcome
    Chemical Substances Anti-Bacterial Agents ; Dioxolanes ; Fluoroquinolones ; Piperazines ; Quinolones ; prulifloxacin (J42298IESW)
    Language English
    Publishing date 2006-02
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 2181279-2
    ISSN 1744-8336 ; 1478-7210
    ISSN (online) 1744-8336
    ISSN 1478-7210
    DOI 10.1586/14787210.4.1.27
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top